A Phase 4 interventional study of Morning administration of CDK4/6 inhibitor and Evening administration of CDK4/6 inhibitor in Metastatic Breast Cancer and Metastatic Prostate Cancer, sponsored by Ottawa Hospital Research Institute. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by Ottawa Hospital Research Institute · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute — 4 open to participants now, 7 under way, none of them phase 3. Breast Neoplasms · Ottawa Hospital Research Institute.
Among the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, this one is the 31st largest by planned enrollment of the 40 interventional ones that give a count, is the only one that started in 2026, is one of 20 in phase 4, and was the 44th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →4 of the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute are open now, in 1 country. Recruiting first, the newest first:
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 70+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18–90 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 121 across the 40 interventional studies, 171 across the 4 observational. Of the 27 that completed or were terminated, 6 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ottawa Hospital Research Institute is the lead sponsor of 547 studies on the registry; 99 are open to participants now.
1 of the studies in Breast Neoplasms by Ottawa Hospital Research Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07252726Ottawa Hospital Research InstituteEvaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The REaCT-CHRONO-MetBP Pilot study will compare morning and evening administration of endocrine-based therapy in metastatic breast and prostate cancers.
Participants with metastatic breast or prostate cancer will be randomly placed in one of two groups: a morning group and an evening group. The group assignment will determine whether they take their endocrine therapy in the morning or the evening. The primary outcome of this pilot study is to evaluate the feasibility of study procedures in order to conduct a larger definitive trial in the future. The secondary outcomes include comparing quality of life, tolerability, and efficacy outcomes between the morning and evening groups for each of the two cancer cohorts (metastatic breast and prostate cancer).
Cohort A (Breast Cohort) Inclusion Criteria
Cohort A (Breast Cohort) Exclusion Criteria
Cohort B (Prostate Cancer) Inclusion Criteria
Cohort B (Prostate Cancer) Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with metastatic breast cancer in this arm are assigned morning administration of CDK4/6 inhibitor.
Other: Morning administration of CDK4/6 inhibitor
Participants with metastatic breast cancer in this arm are assigned evening administration of CDK4/6 inhibitor.
Other: Evening administration of CDK4/6 inhibitor
Participants with metastatic prostate cancer in this arm are assigned morning administration of ARPI.
Other: Morning administration of ARPI
Participants with metastatic prostate cancer in this arm are assigned evening administration of ARPI.
Other: Evening administration of ARPI
Morning administration of cyclin-dependent kinase (CDK) 4/6 inhibitor defined as, within one hour of the participant wake up time.
Evening administration of cyclin-dependent kinase (CDK) 4/6 inhibitor defined as, within one hour of the participant bedtime.
Morning administration of androgen receptor pathway inhibitors (ARPI) defined as, within one hour of the patient wake up time.
Evening administration of androgen receptor pathway inhibitors (ARPI) defined as, within one hour of the patient bedtime.
Feasibility: accrual per site
Feasibility will be assessed according to a combination of metrics, including the accrual of at least 25 patients per cohort in one year for a total of three sites
Time frame: 1 year
Feasibility: participation rate
Feasibility will be assessed according to a combination of metrics, including participation rate of at least 60% among patients approached.
Time frame: The accrual period, approximately 1 year
Feasibility: number of participants who received allocated intervention
Feasibility will be assessed according to a combination of metrics, including at least 80% of enrolled patients receive treatment as per their allocated intervention for at least 4 weeks.
Time frame: 4 weeks
Health-related quality of life: Functional Assessment of Cancer Therapy-General
Health-related quality of life using Functional Assessment of Cancer Therapy-General (FACT-G). Cohort A and Cohort B will answer the FACT-G. FACT-G has a score range of 0 to 108. Higher scores indicate better quality of life.
Time frame: Baseline and 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years
Health-related quality of life: Functional Assessment of Cancer Therapy-Endocrine Symptoms
Health-related quality of life using Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES). Cohort A and Cohort B will answer the FACT-ES. FACT-ES has a score range of 0 to 184. Higher scores indicate better quality of life.
Time frame: Baseline and 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years
Health-related quality of life: Functional Assessment of Cancer Therapy-Breast
Health-related quality of life using Functional Assessment of Cancer Therapy-Breast (FACT-B). Cohort A will complete the FACT-B. FACT-B has a score range of 0 to 148. Higher scores indicate better quality of life.
Time frame: Baseline and 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years
Health-related quality of life: Functional Assessment of Cancer Therapy-Prostate
Health-related quality of life using Functional Assessment of Cancer Therapy-Prostate (FACT-P). Cohort B will complete the FACT-P. FACT-P has a score range of 0 to 156. Higher scores indicate better quality of life.
Time frame: Baseline and 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years
Number of changes in treatment dose
Time frame: 5 years
Number of treatment interruptions
Time frame: 5 years
Number of treatment discontinuations
Time frame: 5 years
Cohort A's adverse events of interest
The number of participants in Cohort A that experience QTc prolongation, neutropenia, febrile neutropenia, hepatobiliary function.
Time frame: 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years
Cohort B's adverse events of interest
The number of participants in Cohort B that experience hypertension, hyperglycemia, rash, hypothyroidism, fatigue.
Time frame: 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years
Adherence to treatment
Adherence to treatment measured by the Five-Item Medication Adherence Report Scale (MARS-5 score). The MARS-5 has a range of 5-25. Higher scores indicate high adherence.
Time frame: 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years
Participant preference in dose timing
Participants rank their preference on a scale of 0 to 10, where 0=prefer to take treatment in the morning, 5=no preference, 10=prefer to take treatment in the evening.
Time frame: Baseline
Time to second-line systemic treatment
Time from the randomization to start of second-line systematic treatment. This is reported on the Health Care Provider (HCP) follow up questionnaire which is completed at the various timepoints outlined in the time frame.
Time frame: 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years
Overall survival
Overall survival is the time from randomization to death from any cause. Survival status (yes/no) will be checked throughout the study at the various timepoints outlined in the time frame.
Time frame: 4-, 12-, 26-, 52-weeks, 2-years, 3-years, 4-years, 5-years, 6-years post-randomization.
PSA reduction at 6 months
Cohort B only: prostate-specific antigen reduction.
Time frame: 6 months
Plan to share: No
Started Feb 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.
Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 13 months is below that.
Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ottawa Hospital Research Institute →